316 related articles for article (PubMed ID: 21444680)
1. Therapeutic implications of the emerging molecular biology of uveal melanoma.
Patel M; Smyth E; Chapman PB; Wolchok JD; Schwartz GK; Abramson DH; Carvajal RD
Clin Cancer Res; 2011 Apr; 17(8):2087-100. PubMed ID: 21444680
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy for uveal melanoma.
Triozzi PL; Eng C; Singh AD
Cancer Treat Rev; 2008 May; 34(3):247-58. PubMed ID: 18226859
[TBL] [Abstract][Full Text] [Related]
3. Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma.
Chua V; Lapadula D; Randolph C; Benovic JL; Wedegaertner PB; Aplin AE
Mol Cancer Res; 2017 May; 15(5):501-506. PubMed ID: 28223438
[TBL] [Abstract][Full Text] [Related]
4. Uveal melanoma and macular degeneration: molecular biology and potential therapeutic applications.
Economou MA
Acta Ophthalmol; 2008 Dec; 86(8):930-1. PubMed ID: 19086934
[TBL] [Abstract][Full Text] [Related]
5. The molecular pathology of cutaneous melanoma.
Bogenrieder T; Herlyn M
Cancer Biomark; 2010; 9(1-6):267-86. PubMed ID: 22112480
[TBL] [Abstract][Full Text] [Related]
6. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
[TBL] [Abstract][Full Text] [Related]
7. Metastatic uveal melanoma: biology and emerging treatments.
Woodman SE
Cancer J; 2012; 18(2):148-52. PubMed ID: 22453016
[TBL] [Abstract][Full Text] [Related]
8. Ocular melanoma: what's new?
Leyvraz S; Keilholz U
Curr Opin Oncol; 2012 Mar; 24(2):162-9. PubMed ID: 22234256
[TBL] [Abstract][Full Text] [Related]
9. What hope for the future? GNAQ and uveal melanoma.
Sisley K; Doherty R; Cross NA
Br J Ophthalmol; 2011 May; 95(5):620-3. PubMed ID: 21378004
[TBL] [Abstract][Full Text] [Related]
10. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
[TBL] [Abstract][Full Text] [Related]
11. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
[TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic strategies and targets in advanced uveal melanoma.
Chua V; Aplin AE
Curr Opin Oncol; 2018 Mar; 30(2):134-141. PubMed ID: 29206651
[TBL] [Abstract][Full Text] [Related]
13. New therapeutic agents in uveal melanoma.
Velho TR; Kapiteijn E; Jager MJ
Anticancer Res; 2012 Jul; 32(7):2591-8. PubMed ID: 22753717
[TBL] [Abstract][Full Text] [Related]
14. Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
Cheng H; Chua V; Liao C; Purwin TJ; Terai M; Kageyama K; Davies MA; Sato T; Aplin AE
Mol Cancer Ther; 2017 Mar; 16(3):516-528. PubMed ID: 28138035
[TBL] [Abstract][Full Text] [Related]
15. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
Musi E; Ambrosini G; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
[TBL] [Abstract][Full Text] [Related]
16. Biology of advanced uveal melanoma and next steps for clinical therapeutics.
Luke JJ; Triozzi PL; McKenna KC; Van Meir EG; Gershenwald JE; Bastian BC; Gutkind JS; Bowcock AM; Streicher HZ; Patel PM; Sato T; Sossman JA; Sznol M; Welch J; Thurin M; Selig S; Flaherty KT; Carvajal RD
Pigment Cell Melanoma Res; 2015 Mar; 28(2):135-47. PubMed ID: 25113308
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death.
Ambrosini G; Musi E; Ho AL; de Stanchina E; Schwartz GK
Mol Cancer Ther; 2013 May; 12(5):768-76. PubMed ID: 23443802
[TBL] [Abstract][Full Text] [Related]
18. Targeting GNAQ/11 through PKC inhibition in uveal melanoma.
Lietman CD; McKean M
Cancer Gene Ther; 2022 Dec; 29(12):1809-1813. PubMed ID: 35181742
[TBL] [Abstract][Full Text] [Related]
19. Uveal melanoma and GNA11 mutations: a new piece added to the puzzle.
Besaratinia A; Pfeifer GP
Pigment Cell Melanoma Res; 2011 Feb; 24(1):18-20. PubMed ID: 21159145
[No Abstract] [Full Text] [Related]
20. GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.
Moore AR; Ran L; Guan Y; Sher JJ; Hitchman TD; Zhang JQ; Hwang C; Walzak EG; Shoushtari AN; Monette S; Murali R; Wiesner T; Griewank KG; Chi P; Chen Y
Cell Rep; 2018 Feb; 22(9):2455-2468. PubMed ID: 29490280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
